Nifty
:
15746.45
Sensex
:
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)
Nifty
Sensex
:
:
15746.45
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)

Cadila Healthcare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
52/99

BSE: 532321 | NSE: CADILAHC

NSE BSE
598.75
27-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  615.00
  •  622.00
  •  591.00
  •  605.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  6212666
  •  37653.71
  •  673.70
  •  350.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 62,151.41
  • 29.13
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 65,855.61
  • 0.58%
  • 4.78

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 1.01%
  • 7.31%
  • FII
  • DII
  • Others
  • 4.65%
  • 10.08%
  • 2.07%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.12
  • 10.00
  • 4.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.93
  • 11.92
  • 2.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.32
  • 7.49
  • 5.00

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.92
  • 25.88
  • 21.05

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.38
  • 4.55
  • 3.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.13
  • 16.50
  • 13.76

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
3,846.70
3,752.10
2.52%
3,795.60
3,638.10
4.33%
3,820.00
3,366.60
13.47%
3,639.90
3,496.30
4.11%
Expenses
2,991.40
2,960.90
1.03%
2,988.70
2,940.30
1.65%
2,956.60
2,731.00
8.26%
2,824.50
2,837.60
-0.46%
EBITDA
855.30
791.20
8.10%
806.90
697.80
15.63%
863.40
635.60
35.84%
815.40
658.70
23.79%
EBIDTM
22.23%
21.09%
21.26%
19.18%
22.60%
18.88%
22.40%
18.84%
Other Income
-40.30
44.30
-
27.50
20.10
36.82%
27.50
26.90
2.23%
22.50
22.60
-0.44%
Interest
23.30
82.50
-71.76%
26.80
80.50
-66.71%
45.70
89.70
-49.05%
67.70
89.10
-24.02%
Depreciation
188.60
178.50
5.66%
180.40
174.10
3.62%
179.00
172.30
3.89%
176.80
171.60
3.03%
PBT
530.00
522.00
1.53%
627.20
457.10
37.21%
534.20
122.40
336.44%
593.40
393.90
50.65%
Tax
-201.60
108.50
-
114.70
92.70
23.73%
110.60
39.50
180.00%
123.50
79.10
56.13%
PAT
731.60
413.50
76.93%
512.50
364.40
40.64%
423.60
82.90
410.98%
469.90
314.80
49.27%
PATM
19.02%
11.02%
13.50%
10.02%
11.09%
2.46%
12.91%
9.00%
EPS
6.63
3.83
73.11%
5.15
3.65
41.10%
4.62
1.05
340.00%
4.43
2.96
49.66%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
-
15,102.20
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
Net Sales Growth
-
5.96%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
 
Cost Of Goods Sold
-
4,472.50
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
Gross Profit
-
10,629.70
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
GP Margin
-
70.39%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
Total Expenditure
-
11,763.60
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
Power & Fuel Cost
-
234.50
252.90
231.60
211.40
174.50
155.40
145.40
129.70
124.40
93.40
% Of Sales
-
1.55%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
1.96%
1.77%
Employee Cost
-
2,254.80
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
818.40
679.90
% Of Sales
-
14.93%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
12.87%
12.92%
Manufacturing Exp.
-
2,353.80
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
897.30
718.90
% Of Sales
-
15.59%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
14.11%
13.66%
General & Admin Exp.
-
385.70
582.60
583.40
398.70
466.00
356.40
326.80
302.70
342.20
272.60
% Of Sales
-
2.55%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
5.38%
5.18%
Selling & Distn. Exp.
-
1,477.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
857.50
767.40
% Of Sales
-
9.78%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
13.49%
14.58%
Miscellaneous Exp.
-
584.70
525.90
371.20
404.40
502.60
416.10
330.50
295.20
157.40
767.40
% Of Sales
-
3.87%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
2.48%
3.52%
EBITDA
-
3,338.60
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
EBITDA Margin
-
22.11%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
Other Income
-
44.90
117.10
208.50
133.00
147.10
116.60
57.20
85.90
38.40
53.00
Interest
-
168.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
168.70
182.70
Depreciation
-
724.80
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
PBT
-
2,489.90
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
Tax
-
147.20
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
Tax Rate
-
6.44%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
PAT
-
2,086.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
PAT before Minority Interest
-
2,137.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
Minority Interest
-
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
PAT Margin
-
13.81%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
PAT Growth
-
81.76%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
 
EPS
-
20.38
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
Non-Current Liabilities
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
Secured Loans
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
901.90
Unsecured Loans
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
Long Term Provisions
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
Current Liabilities
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
Trade Payables
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
Other Current Liabilities
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
Short Term Borrowings
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
Short Term Provisions
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
Total Liabilities
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
Net Block
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
Gross Block
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
Accumulated Depreciation
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
Non Current Assets
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
Capital Work in Progress
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
Non Current Investment
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
Long Term Loans & Adv.
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
Other Non Current Assets
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
Current Assets
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
Current Investments
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
Inventories
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
Sundry Debtors
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
Cash & Bank
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
Other Current Assets
1,265.30
441.60
496.00
520.70
348.50
358.90
311.50
323.50
345.90
332.00
Short Term Loans & Adv.
814.90
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
Net Current Assets
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
Total Assets
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,293.00
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
PBT
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
Adjustment
1,166.40
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
315.90
320.90
Changes in Working Capital
186.80
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
Cash after chg. in Working capital
3,638.00
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
0.00
-38.80
Cash From Investing Activity
-722.50
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
Net Fixed Assets
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
Net Investments
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
Others
-193.20
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
Cash from Financing Activity
-2,548.90
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
Net Cash Inflow / Outflow
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
Opening Cash & Equivalents
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
Closing Cash & Equivalent
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
ROA
9.37%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
ROE
18.30%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
ROCE
13.65%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
18.21%
24.01%
Fixed Asset Turnover
0.89
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
Receivable days
82.06
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
Inventory Days
72.81
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
Payable days
66.13
64.85
68.81
68.11
74.18
65.30
55.05
49.83
43.54
49.87
Cash Conversion Cycle
88.74
102.77
100.73
78.94
62.42
52.51
61.46
65.78
74.05
72.45
Total Debt/Equity
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
Interest Cover
14.54
5.38
13.17
21.87
26.55
40.75
22.29
8.98
5.79
5.35

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Zydus Cadila gets tentative approval from USFDA to market Ibrutinib Tablets
    22nd Jul 2021, 10:31 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Cadila Healthcare’s arm completes sale of animal health business for Rs 2,921 crore
    15th Jul 2021, 12:29 PM

    The transaction of sale and disposal is completed /closed on July 14, 2021

    Read More
  • Cadila Healthcare’s arm recalling 21,000 bottles of metformin hydrochloride extended-release tablets
    5th Jul 2021, 10:31 AM

    Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus

    Read More
  • Zydus Cadila gets final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
    2nd Jul 2021, 14:05 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila applies to DCGI for EUA to launch ZyCoV-D
    1st Jul 2021, 10:12 AM

    This was also the first time that any COVID-19 vaccine has been tested in adolescent population in the 12-18 years age group in India

    Read More
  • Zydus Cadila gets tentative approval to market Pemetrexed for Injection
    25th Jun 2021, 10:57 AM

    Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma

    Read More
  • Zydus Cadila gets tentative approval to market Fingolimod Capsules
    24th Jun 2021, 11:40 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Cadila Healthcare signs agreement to extend tenure of JVA with Bayer
    21st Jun 2021, 11:44 AM

    The amendment is to extend the term of the JVA for a period of three years till May 1, 2024

    Read More
  • Zydus Cadila receives USFDA’s tentative approval for Brivaracetam Tablets
    14th Jun 2021, 09:02 AM

    Brivaracetam is used to treat partial-onset of seizures

    Read More
  • Zydus Cadila gets tentative approval to market Osimertinib Tablets
    3rd Jun 2021, 11:08 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila receives final approval from USFDA for Fluphenazine Hydrochloride Tablets
    29th May 2021, 12:08 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Cadila Healthcare reports 73% rise in Q4 consolidated net profit
    29th May 2021, 10:50 AM

    The company has reported a standalone net profit of Rs 464.70 crore for the quarter ended March 31, 2021

    Read More
  • Zydus Cadila introduces new feature in packaging of its critical drugs
    28th May 2021, 13:59 PM

    All that one needs to do is scratch the code and immediately verify this on an app or website, in no time

    Read More
  • Zydus, TLC sign agreement to market Liposomal Amphotericin B
    26th May 2021, 12:52 PM

    Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus

    Read More
  • Zydus Cadila launches Trastuzumab Emtansine
    24th May 2021, 10:18 AM

    The current MRP of existing Trastuzumab Emtansine drug is Rs 1,59,225 for 100 mg vial. Ujvira will be available in two strengths, 100 mg and 160 mg

    Read More
  • Cadila Healthcare’s arm enters into BTA with Zenex Animal Health
    12th May 2021, 11:34 AM

    The company has entered into BTA for disposal of its Animal Healthcare Established Markets Undertaking

    Read More
  • Cadila Healthcare inks pact to extend tenure of joint venture with Bayer
    5th May 2021, 15:10 PM

    The company has signed an agreement to extend the tenure of the joint venture with a Bayer Group firm for a period of two months

    Read More
  • Zydus Cadila gets emergency use approval of ‘Virafin’ for treating moderate Covid-19 infection in adults
    24th Apr 2021, 08:39 AM

    When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications

    Read More
  • Zydus gets emergency use approval from DCGI for use of ‘Virafin’ in treating moderate COVID-19 infection
    23rd Apr 2021, 15:23 PM

    Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup

    Read More
  • Zydus Cadila gets approval from USFDA to market Propafenone Hydrochloride Extended-Release Capsules
    23rd Apr 2021, 10:58 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.